<DOC>
	<DOC>NCT00539214</DOC>
	<brief_summary>- To compare the effect of pramipexole on depressive symptoms in early and advanced PD patients - To evaluate the course of depressive symptoms measured with UPDRS Part I (mentation, behavior and mood) and with HADS-D under pramipexole treatment - To investigate whether improvement of depressive symptoms is linked to improvement in motor function (UPDRS Part III)</brief_summary>
	<brief_title>Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease</brief_title>
	<detailed_description>Study Design:</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criteria: 1. Idiopathic Parkinsons disease with or without fluctuations 2. Indication for treatment with Sifrol® 3. Male or female patients of age 4. Presence of at least mild depressive symptoms (as judged by the treating physician) 5. Ability to reliably complete a selfrating scale (HADS) Exclusion criteria: 1. Any contraindications according to the Summary of Product Characteristics (SPC): hypersensitivity to pramipexole or to any of the excipients. 2. Ongoing treatment with Sifrol®.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>